Alignment Healthcare, Inc. - Common Stock (ALHC)
14.89
0.00 (0.00%)
Alignment Healthcare Inc is a leading healthcare company that focuses on providing innovative and personalized health care solutions, primarily for seniors
The company utilizes a technology-driven approach to deliver high-quality, value-based care, ensuring that patients receive tailored support and resources to manage their health effectively. By leveraging data analytics and a network of healthcare professionals, Alignment aims to improve health outcomes while enhancing patient experiences and reducing healthcare costs. The company emphasizes preventive care and proactive health management, positioning itself as a pivotal player in the evolving landscape of healthcare services for aging populations.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the health insurance providers industry, including Molina Healthcare (NYSEMOH) and its peers.
Via StockStory · March 5, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQPGNY) and its peers.
Via StockStory · March 3, 2025

Top mid-cap stock gainers in past week: Root, Bridge Investment Group, Huron Consulting, Medical Properties Trust, ZoomInfo Technologies, Lantheus Holdings, Alignment Healthcare, VSE. Analysts raise price forecasts.
Via Benzinga · March 2, 2025

Shares of health insurance company Alignment Healthcare (NASDAQALHC)
jumped 17.5% in the afternoon session after the company reported strong fourth-quarter 2024 results and provided optimistic full-year revenue and EBITDA guidance, exceeding analysts' expectations. Sales jumped 50.7% from last year, fueled by a 58.6% rise in health plan members, reaching 189,100 by year-end. Profitability improved as the company logged its first full year of positive adjusted EBITDA. Zooming out, this quarter underscored the company's ability to scale efficiently while positioning itself for sustained growth.
Via StockStory · February 28, 2025

Via Benzinga · February 24, 2025

Health insurance company Alignment Healthcare (NASDAQALHC) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 50.7% year on year to $701.2 million. On top of that, next quarter’s revenue guidance ($887.5 million at the midpoint) was surprisingly good and 4.1% above what analysts were expecting. Its GAAP loss of $0.16 per share was 11% above analysts’ consensus estimates.
Via StockStory · February 27, 2025

Health insurance company Alignment Healthcare (NASDAQALHC)
will be reporting earnings tomorrow after market hours. Here’s what to look for.
Via StockStory · February 26, 2025

Alignment Healthcare has been on fire lately. In the past six months alone, the company’s stock price has rocketed 60.1%, reaching $13.88 per share. This performance may have investors wondering how to approach the situation.
Via StockStory · February 14, 2025

Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
Via Benzinga · January 19, 2025

Via Benzinga · January 2, 2025

Via Benzinga · October 28, 2024

Via Benzinga · November 20, 2024

Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization.
Via Benzinga · November 9, 2024

Via Benzinga · October 11, 2024

Via Benzinga · October 2, 2024

Via Benzinga · August 14, 2024

Via Benzinga · July 26, 2024

7 mid-cap stocks with impressive gains last week: CDE, MPW, NGD, RH, AUR, TWST, ALHC. Positive news and financial results drove the surge.
Via Benzinga · September 15, 2024

Via Benzinga · May 30, 2024

Via Benzinga · May 30, 2024

Alignment Healthcare earnings: EPS loss $(0.25), sales surge 43.1% to $628.6M, beats guidance. Health plan membership up 50.5% Y/Y. Q2 revenue guidance: $625M-$635M. FY 2024 sales raised to $2.495B-$2.525B. Expert outlook: Favorable Q1, stable cost trends.
Via Benzinga · May 3, 2024